Kyorin Pharmaceutical Co (TSE:4569) Retained Earnings: 円131,545 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,062.00
GF Value 円1,581.58
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Retained Earnings?

Kyorin Pharmaceutical Co TSE:4569 -2.03% 74 Retained Earnings is 円131,545 Mil as of Mar. 2026. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,581.58 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Kyorin Pharmaceutical Co's retained earnings for the quarter that ended in Mar. 2026 was 円131,545 Mil.

Kyorin Pharmaceutical Co's quarterly retained earnings increased from Sep. 2025 (円130,711 Mil) to Dec. 2025 (円132,173 Mil) but then declined from Dec. 2025 (円132,173 Mil) to Mar. 2026 (円131,545 Mil).

Kyorin Pharmaceutical Co's annual retained earnings increased from Mar. 2024 (円136,726 Mil) to Mar. 2025 (円142,789 Mil) but then declined from Mar. 2025 (円142,789 Mil) to Mar. 2026 (円131,545 Mil).


Kyorin Pharmaceutical Co  (TSE:4569) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Kyorin Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Retained Earnings Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132,710.00 134,396.00 136,726.00 142,789.00 131,545.00

Kyorin Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142,789.00 131,317.00 130,711.00 132,173.00 131,545.00
TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of 円131,545 Mil mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Retained Earnings of 円131,545 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Kyorin Pharmaceutical Co and its competitors.
Is Kyorin Pharmaceutical Co's Retained Earnings too high?
Kyorin Pharmaceutical Co's current Retained Earnings is 円131,545 Mil. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Retained Earnings compare to ZTS?
Kyorin Pharmaceutical Co's Retained Earnings of 円131,545 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Kyorin Pharmaceutical Co and its competitors. Kyorin Pharmaceutical Co's current Retained Earnings is 円131,545 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Significantly Undervalued. The stock's GF Value™ is 円1,581.58, compared to a current price of 円1,062.00 — trading 32.9% below its estimated fair value. The current Retained Earnings is 円131,545 Mil. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Retained Earnings is 円131,545 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,062.00 is trading 32.9% below its estimated GF Value™ of 円1,581.58. GuruFocus considers Kyorin Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for TSE:4569:

  • Retained Earnings: 円131,545 Mil
  • GF Value™: 円1,581.58 vs. price of 円1,062.00 (32.9% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,062.00
Price
円1,581.58
GF Value